• Study Understanding Pre-Exposure Prophylaxis of Novel Antibodies (SUPERNOVA)

    AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.

  • The Effects of Nirmatrelvir/Ritonavir (Nirmatrelvir/ritonavir) on Infectivity and Quality of Life Amongst Low to Moderate Risk Individuals with COVID-19. Can This Return Us to Normalcy Faster?

  • A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Participants With Standard Risk for Developing Severe Disease